SAN 📈 Sanofi SA - Overview

Sanofi, a multinational healthcare company, is engaged in the research, development, manufacture, and marketing of a wide range of therapeutic solutions, with operations spanning the United States, Europe, Canada, and international markets. The company's business is organized into three primary segments: Pharmaceuticals, Vaccines, and Consumer Healthcare, each focusing on distinct aspects of healthcare. The Pharmaceuticals segment offers specialty care products, including DUPIXENT, as well as treatments for neurology and immunology, rare diseases, oncology, and rare blood disorders. Additionally, it provides medicines for managing diabetes and cardiovascular diseases, along with established prescription products.

The Vaccines segment is responsible for the development and distribution of various vaccines, including those for poliomyelitis, pertussis, and hib for pediatric use, as well as influenza, booster, meningitis, and travel and endemic vaccines such as hepatitis A, typhoid, cholera, yellow fever, and rabies. This diverse portfolio underscores Sanofi's commitment to preventing and controlling infectious diseases globally. Furthermore, the Consumer Healthcare segment offers a broad array of over-the-counter products, including those for cough, cold, and flu, allergy, and pain care, as well as products promoting physical, mental, and digestive wellness. The company also caters to various skincare needs, including itching, hydration, aging, cracking, overnight, and specialty skincare requirements like eczema, reflecting its comprehensive approach to consumer health.

Sanofi has established numerous collaborations and license agreements with other companies to advance its research and development pipeline. For instance, it has a collaboration with Exscientia to develop up to 15 novel small-molecule therapies for oncology and immunology, and with ABL Bio, Inc. to develop ABL301, a potential treatment for alpha-synucleinopathies. The company also partners with Blackstone Life Sciences to support pivotal studies and clinical development programs, and with Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer treatment. Additionally, Sanofi collaborates with IGM Biosciences, Inc. on the development, manufacture, and commercialization of IgM antibodies, and with Skyhawk Therapeutics, Inc. to discover and develop novel small molecules. Its partnership with Adagene Inc. focuses on the discovery and development of antibody-based therapies, while collaborations with Scribe Therapeutics Inc. and Provention Bio, Inc. aim to advance genome editing technologies and the commercialization of teplizumab, respectively.

Originally known as Sanofi-Aventis, the company changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France. With a rich history and a strong presence in the global healthcare industry, Sanofi continues to innovate and expand its portfolio of therapeutic solutions. For more information, the company's website can be accessed at https://www.sanofi.com, and its stock is listed with the ISIN FR0000120578 as common stock, categorized under the GICS Sub Industry: Pharmaceuticals.